Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0477 | bicalutamide

Molecular Formula C18H14F4N2O4S
Molecular Weight 430.4
Structure
State solid
Clearance * Apparent oral cl=0.32 L/h [Normal Males]
Protein binding 0.96
Half life 5.9 days
Absorption Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.

L

L02BB03 Bicalutamide


[L02BB] Anti-androgens


[L02B] HORMONE ANTAGONISTS AND RELATED AGENTS


[L02] ENDOCRINE THERAPY


[L] Antineoplastic and immunomodulating agents

L02AE51 Leuprorelin and bicalutamide


[L02AE] Gonadotropin releasing hormone analogues


[L02A] HORMONES AND RELATED AGENTS


[L02] ENDOCRINE THERAPY


[L] Antineoplastic and immunomodulating agents

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay decrease 53

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 265 companies from 18 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H315 (93.21%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (93.21%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (92.83%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide 357B065
    4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide 90357-06-5
    A803039 AB0008136 AB00639963-06
    AB00639963-08 AB00639963-09 AB00639963_10
    AC-4232 ACT06291 AK544272
    AKOS015895073 AOB5596 API0001710
    AT-9158 B3206 BCP02110
    BCP9000408 BCPP000337 BDBM18525
    BRD-A29485665-001-03-7 BRN 5364666 Bicalutamide (CDX)
    Bicalutamide (CDX), >=98% (HPLC), powder Bicalutamide (Casodex) Bicalutamide (JAN/USP/INN)
    Bicalutamide - Casodex Bicalutamide [USAN:INN:BAN] Bicalutamide [USAN:USP:INN:BAN]
    Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard Bicalutamide(Casodex) Bicalutamide, 97%
    Bicalutamide, British Pharmacopoeia (BP) Reference Standard Bicalutamide, European Pharmacopoeia (EP) Reference Standard Bicalutamide, Pharmaceutical Secondary Standard
    Bicalutamide, United States Pharmacopeia (USP) Reference Standard Bicalutamine C08160
    C18H14F4N2O4S CB0180 CCG-100951
    CCG-220876 CCG-222330 CCRIS 8728
    CHEBI:144093 CHEBI:91617 CHEMBL409
    CPD000466329 CS-1296 Calutide
    Casodex Casodex (TN) Certified Reference Material
    Cosudex D00961 DB-041165
    DB01128 DTXSID2022678 EX-A962
    FT-0080576 FT-0618286 GTPL2863
    HMS2051B13 HMS2089N12 HMS2232H03
    HMS3263M13 HMS3372K05 HMS3393B13
    HMS3654K18 HMS3714P13 HSDB 7655
    HY-14249 ICI 176,334 ICI 176334
    ICI-176334 ICI176,334-1 J10442
    KS-00000XEI KS-1161 Kalumid
    LKJPYSCBVHEWIU-UHFFFAOYSA-N LP01026 LS-119125
    MFCD00869971 MLS000759437 MLS001424047
    N-(4-cyano-3-(trifluoromethyl)phenyl) N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
    N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide
    N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide NC00201
    NCGC00167977-01 NCGC00167977-02 NCGC00167977-03
    NCGC00167977-09 NCGC00261711-01 NSC-722665
    NSC-759816 NSC722665 NSC759816
    PRO113 Pharmakon1600-01504827 Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-
    Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- PubChem18237 Q1988832
    Raffolutil SAM001246612 SB17301
    SC-17332 SCHEMBL3611 SMR000466329
    SR-01000759410 SR-01000759410-4 SR-01000759410-5
    SW197581-4 Tox21_501026 bicalutamide
    propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-); s1190

    DrugBank Name bicalutamide
    DrugBank DB01128
    CAS Number 113299-38-0, 113299-40-4, 1185035-71-5, 90357-06-5
    PubChem Compound 2375
    KEGG Compound ID C08160
    KEGG Drug D00961
    ChEBI 3090